Our research expertise spans cancer genomics, DNA damage, RNA biology, and drug development. We are also expanding our focus on drug delivery, particularly through nanotechnology-based methods for delivering small RNA mimics and inhibitors.
News
- Greehey CCRI Researcher Awarded Grant to Advance RNA-Based Therapy for Aggressive Pediatric Brain Cancer
- mBio: Identification and characterization of a SARS-CoV-2 Mpro G23 deletion ensitrelvir-resistant mutant (Gupta Lab)
- Nature Structural & Molecular Biology: Structural insight into how RAD51 paralog exchange regulates RAD51 filament formation (Sung Lab, Hromas, Zhou, Zhao, Wasmuth, Olsen)
- David Libich, PhD to Receive CPRIT Grant to Study, “A Novel Approach to Targeting Ewing Sarcoma.”
- Advancing Cancer Research from the Ground Up: Introducing the Greehey CCRI Xenograft & Cell Lines Core
Events
Greehey CCRI Seminar Series: Dima Kozakov, PhD (UT Austin)
Presentation title: “Modeling and modulating disease at systems level with physics aware deep learning”
Greehey CCRI Spring ’26 Seminar Series: Reuben Harris, PhD (UTHSA)
Presentation title: “Progress on the development of novel drugs for viral proteases”
Greehey CCRI Seminar Series: Lingtao Jin, PhD (UTHSA)
Presentation title: “Kinase Signaling in Cancer Drug Resistance”